CONMED CORPORATION Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CONMED CORPORATION (CNMD) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $15.56 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-17
- CONMED CORPORATION right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $7.01M.
- CONMED CORPORATION right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-09-30 was $4.94M.
- CONMED CORPORATION right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-06-30 was $405.00K.
- CONMED CORPORATION right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-03-31 was $444.00K.
- CONMED CORPORATION right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $15.56M, a 51.74% decline from fiscal 2024.
- CONMED CORPORATION right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $32.23M, a 449.71% increase from fiscal 2023.
- CONMED CORPORATION right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $5.86M, a 13.49% increase from fiscal 2022.
- CONMED CORPORATION right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $5.17M, a 9.84% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $15.56M 10-K · filed 2026-02-17 | |||
| 2024-12-31 | $32.23M 10-K · filed 2026-02-17 | |||
| 2023-12-31 | $5.86M 10-K · filed 2026-02-17 | |||
| 2022-12-31 | $5.17M 10-K · filed 2025-02-18 | |||
| 2021-12-31 | $4.70M 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $4.24M 10-K · filed 2023-02-21 | |||
| 2019-12-31 | $7.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $11.95M derived: sum of 2 quarters · filed 2022-02-22 | $12.36M derived: sum of 3 quarters · filed 2022-02-22 | $12.80M 10-K · filed 2022-02-22 |
| 2019-09-30 | $4.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $5.34M derived: sum of 2 quarters · filed 2019-10-31 | $5.79M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $405.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $849.00K 10-Q · filed 2019-08-01 | ||
| 2019-03-31 | $444.00K 10-Q · filed 2019-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |